2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2974 TCIRG1-associated congenital neutropenia: Current understanding and future directions

Vahagn Makaryan, MD, Audrey Anna Bolyard, RN, BSN2, David C. Dale, MD3
1 University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States

Background: TCIRG1 is best known as the gene responsible for autosomal recessive osteopetrosis. More recently, heterozygous TCIRG1 variants have been recognized as a distinct cause of congenital neutropenia, expanding the phenotypic spectrum of this gene beyond skeletal disease. (Makaryan et al; 2014; Rosenthal et al; Genet Epidemiol. 2016; Shinwari et al; Front. Mol Biosci. 2022) Since the initial description of this disorder, accumulating clinical and experimental evidence has demonstrated that specific heterozygous TCIRG1 variants impair the granulopoiesis: suggesting a previously unrecognized role for TCIRG1 in human hematopoiesis. Our group has played a central role in characterizing this disorder and has identified seven unrelated families with TCIRG1-associated neutropenia, representing the largest cohort reported to date.

Current Knowledge: Clinical studies have established that affected individuals present with typical chronic neutropenia of variable severity and recurrent bacterial infections while lacking the characteristic skeletal manifestations of recessive TCIRG1 deficiency or evidence of involvement of other organ systems or syndromic features. Genetic studies indicate that disease-associated variants cluster within a very specific region of the gene and appear to act through mechanisms distinct from simple haploinsufficiency.

Functional investigations performed by our group have substantially advanced understanding of this disease. Using patient-derived induced pluripotent stem cells (iPSC) and in vitro granulocytic differentiation assays, we demonstrated that pathogenic TCIRG1 variants directly impair neutrophil differentiation and more importantly, CRISPR/Cas9-mediated gene correction of disease-causing variant restores granulopoiesis, establishing a causal relationship between these variants and neutropenia (Makaryan et al., J Cell Immunol., 2025). These studies provide the first functional validation of TCIRG1 as a congenital neutropenia gene and support a dominant, mutation-specific pathogenic mechanism distinct from the loss-of-function mechanism responsible for osteopetrosis.

Future Directions:
Despite these advances, the molecular basis of TCIRG1-associated neutropenia remains largely unknown. Future studies should define how individual pathogenic variants alter TCIRG1 protein function and identify the downstream pathways responsible for impaired granulopoiesis. Priorities include investigating unfolded protein response, cellular stress signaling and transcriptional regulation during neutrophil differentiation as well as lysosomal biology, vesicular trafficking, endosomal acidification during this disease. An equally important objective is determining whether all pathogenic variants converge on a common molecular pathway or whether multiple mutation-specific mechanisms exist. Finally, additional studies are needed to determine whether other, as yet unidentified, TCIRG1 variants account for unexplained cases of congenital neutropenia.

Conclusions:
Recognition of TCIRG1-associated neutropenia represents one of the most important recent advances in the genetics of congenital neutropenia. Routine inclusion of TCIRG1 in congenital neutropenia gene panels and careful analysis of exome and genome sequencing data will be essential for identifying additional patients and families, refining genotype-phenotype correlations, and accelerating mechanistic and therapeutic studies. Most families with TCIRG1-associated congenital neutropenia have been identified only in recent years, largely due to the inclusion of TCIRG1 in exome sequencing and inherited neutropenia gene panels, together with our worldwide outreach through the Severe Chronic Neutropenia International Registry (SCNIR). We believe that many additional affected individuals and families remain undiagnosed, underscoring the importance of broader genetic testing, increased clinical awareness, and continued international collaboration. Continued dissemination of knowledge regarding this rare disorder to hematologists, immunologists, clinical geneticists, diagnostic laboratories, and the broader scientific community is equally critical to improve recognition, diagnosis, collaborative research, and ultimately patient care.

Vahagn Makaryan, MD: No relevant conflicts of interest to declare.